Clarity Pharmaceuticals, an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, have entered into a targeted copper theranostics (TCTs) manufacturing agreement for Clarity’s U.S. clinical trials.   Evergreen will centrally manufacture and distribute a range of ready-to-use cGMP TCTs for Clarity’s expanding clinical programs acr...